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AbStrAct
No laboratory tests and imaging techniques are recommended for routine use in the ILO/IMO Guidelines on 
the Pre-Employment Medical Examination (PEME) of Seafarers that form the basis for statutory certification. 
However, they are widely used as components of the PEME protocols developed by insurers, employers 
and national maritime authorities in an attempt to predict and reduce the risks from illness whilst working 
at sea. This may be justified on scientific, safety, economic or professional grounds. We propose a rational 
approach for deciding if and when tests can be justified for routine use in assessing a seafarer’s fitness 
for work at sea. This is based on well-established methods for determining the validity of screening tests in 
public health as well as the seafarer demographics. We do not address the well-established use of similar 
tests where illness is suspected but only when they are used for routine PEME screening of all seafarers.
(Int Marit Health 2017; 68, 2: 90–98)
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INtrODUctION
Guidelines on the medical examination of seafarers, 
published by the International labour Organisation (IlO) 
and the International Maritime Organisation (IMO) [1], rec-
ommend that seafarers should not be routinely required 
to have multiple biochemistry, haematology or imaging 
studies. The use of such tests should be limited to situations 
where there is a clinical indication or a well-defined excess 
incidence of a serious disease such as tuberculosis in the 
seafarer’s home population. Nevertheless protocols for 
pre-employment medical examinations (PeMe) developed by 
some national maritime authorities or by insurers, shipping 
agents or companies and by crewing nations do include 
such tests [2]. a review of 19 different PeMe protocols 
reveals that many tests are used, some more commonly 
than others (Fig. 1). 
This article proposes a rational approach for deciding 
if and when such tests can be justified for routine use in 
assessing a seafarer’s fitness for work at sea. 
bAcKGrOUND
The overall aim of the PeMe is to reduce the risk of ill-
ness and/or safety problems whilst the seafarer is working 
at sea. These risks are prioritised differently in different 
PeMe protocols depending on the perspective of the organi-
sation specifying the contents of each protocol [3]. Priorities 
will differ based on the relative importance of personal and 
vessel safety risks, the risk to ship operations, the finan-
cial risk for the shipping company and insurer, the health 
risks to the individual and to others and the reputation of 
the flag. Priorities will also depend on the approach to risk 
management and loss prevention taken by the shipping 
company, crewing agent and insurer.
Qualitative diagnostic tests are normally used in medi-
cal practice to establish a diagnosis, and the test result is 
either “positive”, indicating a specific condition, or “nega-
tive”, indicating the absence of the condition. Quantitative 
tests can be used to establish the seriousness or stage of 
a condition, but sometimes also for the purpose of estab-
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treatment. This is aimed at reducing the long-term risks of 
both acute hypertensive illness and the development of 
other conditions for which hypertension is a known risk fac-
tor, e.g. myocardial infarction and cerebrovascular attacks. 
However, statutory PeMe guidelines suggest that a seafarer 
is fit to go to sea as long as the blood pressure is less than 
160/100 mm Hg. The PeMe examination is looking at the 
likelihood of an incident occurring in the next 2 years, not 
throughout the seafarer’s lifetime. Dependent upon the 
measurement(s) taken at the PeMe, decision trees are 
available to assist the doctor in deciding on permanent/ 
/temporary unfitness or the use of a limited certificate to 
minimise the risk to the seafarer of developing complica-
tions whilst at sea and also to reduce the risk to the ship 
and shipowner of such an incident occurring [5, 6].
when laboratory tests are used in an algorithm that 
“rules in” or “rules out” a seafarer from service at sea, 
based purely on the presence of a disease or risk factor as 
measured by the test, we risk putting healthy employees, 
i.e. those who have almost no increased risk of ill-health 
whilst working at sea, on shore. This could be regarded 
as unjustifiable discrimination and an unethical process 
because it prevents them from working [7]. equally, if in-
appropriate tests are used, we also risk sending a person 
who does have an excess risk of ill-health to work at sea, 
and increasing the exposure to risk for the seafarer, ship, 
shipping company and insurer.
rISK ASSESSMENt IN PEME 
The importance of the identification of a medical condi-
tion or diagnosis lies in the probability of a medical incident 
linked to that diagnosis occurring whilst at sea. The “careful 
clinical assessment and analysis” required by the IMO/IlO 
guidelines [8] implies that an individual risk assessment 
is carried out to determine the risk of a seafarer suffering 
a complication or acute deterioration of a known medical 
condition, or developing a new medical condition based on 
known risk factors during the validity period of the medical 
certificate. Screening asymptomatic individuals for the pres-
ence or absence of a disease or risk factor may be part of 
the risk assessment and can be done by clinical examination 
alone and/or may require the use of further tests. 
ScrEENING tEStS IN  
tHE GENErAL POPULAtION 
Some of the laboratory tests and imaging techniques 
that have been used during seafarer PeMes are essentially 
tests that are more widely used for diagnostic purposes 
based on the suspicion of a disease. Few, if any, have 
been shown to be suitable for screening of asymptomatic 
members of a particular group within the general population 
in order to identify undetected diseases or disease risk 
Figure 1. Number of pre-employment medical examinations 
(PeMe) protocols using a variety of laboratory tests for 
screening
lishing a diagnosis. In the latter case, a cut-off point needs 
to be defined, above or below which further action needs 
to be taken. 
However, having a medical condition is not the same as 
being unfit for service at sea. 
For example, in a seafarer with hypertension, the level 
at which one would start treatment is lower than the level 
at which a seafarer would be seen as unfit to go to sea. 
National guidelines such as those published by the Na-
tional Institute of Health and Care excellence in the United 
Kingdom [4] suggest that a blood pressure of greater than 
140/90 mm Hg requires further investigation and possible 
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factors, in accordance with accepted criteria for evaluation 
of screening tests [9]. The criteria for a beneficial screening 
programme and screening test that focuses on detecting 
disease at an asymptomatic stage to facilitate secondary 
prevention is shown in Table 1. well established population 
screening techniques include blood pressure monitoring 
in the identification of hypertension, mammography for 
the detection of breast cancer and cervical smears for the 
detection of cervical cancer. a wide range of other tests 
have been proposed for use in screening, but their validity 
can often be controversial e.g. prostate specific antigen for 
prostatic cancer detection. 
ScrEENING OF ASYMPtOMAtIc 
SEAFArErS IN PEME
The requirements for a screening programme focusing 
on identification of disease for the purpose of secondary 
prevention are not directly applicable for use as screening 
tests in PeMe. The purpose of PeMe is not to find seafarers 
with asymptomatic disease that could be treated to ensure 
a better outcome for the individual, but rather to identify 
seafarers with an excess probability of having a medical 
incident during the validity period of the certificate that could 
impose a risk to crew, ship and self whilst serving on board. 
Screening for the purpose of identifying asymptomatic sea-
farers that should not go to sea, requires different criteria, 
particularly with respect to the medical condition (Table 2).
The disease in question should be common and its 
natural progression with or without treatment should pos-
sibly cause a significant medical problem within the validity 
period of the certificate. Furthermore, the medical problems 
and incidents associated with the condition may pose a risk 
(health/safety/financial/operational) to the seafarer, ship, 
shipping company or insurer. The test used also needs to 
be appropriate for detection of the disease or risk factor in 
an asymptomatic individual. Furthermore it needs to be safe 
and reasonably priced, with any follow up investigations or 
treatments widely available at a cost that is not prohibitive 
to the seafarer. Most importantly, use of a particular test in 
an asymptomatic population of seafarers should be shown 
to decrease the incidence of illness associated with that 
medical condition or risk factor and therefore decrease 
the risk to the seafarer, ship, shipowner and insurer. That 
is, it will improve risk assessment and risk management.
A SUGGEStED StEPWISE APPrOAcH tO 
tHE APPrOPrIAtENESS OF A ScrEENING 
tESt IN ASYMPtOMAtIc SEAFArErS
IDENtIFIcAtION OF cONDItIONS tHAt  
cAUSE MEDIcAL PrObLEMS At SEA
Only conditions or risk factors that could lead to an 
unacceptable risk on board should lead to a decision of lim-
itation, restriction or unfitness for service at sea. Therefore 
only those conditions should be considered for screening 
during PeMe. If present, the likelihood of a medical incident 
occurring on board within the validity period of the certificate 
must be assessed. ’risk’ in this context is the product of 
probability/likelihood and consequences. This means that 
if the consequences are catastrophic, even a low likelihood 
would lead to a high risk, and conversely, if the likelihood 
is very high, even smaller consequences could lead to an 
unacceptable risk.
Identification of such a disease or risk factor will allow 
further investigation and treatment of that disease to opti-
mise the medical condition of the seafarer and hence maybe 
allow him to continue work without posing an increased 
risk on board. 
rISK MItIGAtION MADE POSSIbLE tHrOUGH 
DEtEctION OF DISEASE
will the detection of the disease or risk factor by the use 
of biochemical tests or imaging techniques make it possible 
to mitigate the risk imposed by the condition? Such mitiga-
Table 1. Criteria for screening programmes and screening tests used 
for detecting disease for the purpose of secondary prevention [9]
For a screening programme to be beneficial the disease in 
question should be
• Common with significant morbidity/mortality
• Readily treatable with a potential cure that increases with  
early detection and that is available to all
In addition the test itself should be
• Capable of detecting a disease before it is apparent clinically
• Safe
• A reasonable cost
• Widely available
• Able to show demonstrably improved outcomes with its use
Table 2. Suggested criteria for screening of asymptomatic  
seafarers
Disease criteria:
• The disease should have the likelihood of medical problems 
occurring whilst serving at sea, causing unacceptable risk to 
ship, crew or self
• Detection of the disease facilitates mitigation of risk
In addition the test itself should be
• Capable of detecting a disease before it is apparent clinically
• Safe
• At a reasonable cost
• Widely available
• Able to show demonstrably improved risk assessment
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that we ideally should have a reference population of can-
didates showing up for a PeMe. The reference values will 
not necessarily be the same in different populations, and 
the reference intervals for a given test applied on people 
seeking employment at sea would vary in different parts 
of the world. In most cases we do not have such an ideal 
reference population, which means that validation of tests 
used in PeMe will be more difficult, as general population 
data will have to be used as a reference. 
The reference interval. reference intervals for laboratory 
tests or imaging studies are set either according to statistical 
parameters or based on reference interval studies, data 
from the literature or the manufacturer, data mining stud-
ies or data from other centres. Usually the central 95% of 
a reference population is regarded as the reference interval, 
with a few accepted variations [10, 11, 12]. This implies 
that the lower 2.5% and the upper 2.5% of the test results 
outside the range are regarded “positive”, whilst those 
within the range are “negative”. On average one healthy 
individual out of 20 will have a test result that is defined as 
positive i.e. a false positive test. The use of multiple tests 
in a PeMe programme or repeat results from the same test 
increases the accumulated number of individuals with false 
positive test results for each subsequent test added. The 
use of many tests without clinical indications and without 
applying discretion to the interpretation of the tests has 
the potential to unnecessarily reject healthy seafarers for 
work at sea.
Test sensitivity and specificity. Sensitivity is the propor-
tion of people with disease who will have a positive test 
result [10, 12], or said in another way, the ability to find the 
individuals with disease. 
If the test has 100% sensitivity, it means that it will 
identify all individuals who have the condition for which we 
are testing. If the test is negative, we can then be sure that 
the individual does not have the disease. In Figure 2 the 
test has a sensitivity of 80% so 8 out of the 10 people with 
the disease are correctly identified by this test. The lower 
the sensitivity, the more people with the condition will not 
be found. relying on the test results from a test with a low 
sensitivity could lead to seafarers with the disease being 
falsely regarded as fit and sent to sea. 
Specificity is the proportion of people without disease 
who will have a negative result [10]. 
If the specificity is 100%, all individuals without disease 
will show a negative test. This means that if the test is posi-
tive, it is certain that the individual has the condition tested 
for. The example in Figure 3 shows a situation where the 
tests identify correctly 85 out of the 90 who do not have 
the disease, meaning that the specificity is 85/90 = 94.4%.
The lower the specificity, the less reliable is the positive 
test result. with a low specificity, a false conclusion of unfit-
tion could be restriction or limitation of medical certificates, 
decisions on temporary or permanent unfitness, the use of 
medication, surgery, glasses, hearing aid, pacemakers or 
setting other specific conditions for a certificate. 
cAPAbILItY OF tHE tESt IN  
DEtEctING tHE DISEASE 
Prevalence. In screening programmes, a certain preva-
lence level is usually required to justify screening the general 
population in order to find cases suitable for secondary 
prevention. This is mainly due to cost-benefit analysis, but 
also to increase the positive predictive value of using the 
test. The higher the prevalence, the better the positive pre-
dictive value, and the lower the negative predictive value, 
and vice versa. To ensure a proper interpretation of test 
results, we need to know something about the prevalence 
in the population of concern.
Prevalence is the proportion, or percentage, of people 
with the disease in the population examined at a given point 
of time, or how common a disease is within a population. all 
cases are included in the numerator, and the denominator 
is the total population [11, 12]. Prevalence varies between 
different groups of people. This is a challenge in a system 
where seafarers are examined in many countries around the 
world, according to internationally applied standards and 
criteria, whilst prevalence rates may vary greatly between 
countries.
Prevalence also depends on whether you are looking 
at a non-selected group such as new seafaring recruits, or 
a group, such as serving seafarers, who have previously 
been selected. 
If there are no old people, no infants, no obese or very 
many obese individuals in the study group, the prevalence 
data for some conditions will change. This will also be the 
case for seafarers who have PeMes at regular intervals, as 
some then cease to work at sea because of medical problems 
found at previous examinations. we rarely have prevalence 
data for the specific group of people from which seafarers 
are recruited and this makes the assessment more difficult, 
and less accurate. However, as all individuals showing up for 
a seafarer medical have signed a self-declaration and will 
undergo a medical examination including a medical history, 
the pre-test likelihood will be influenced by this information 
and with less uncertainty than in the reference population. It 
is also important to note that as prevalence is the number of 
individuals with a certain condition at a certain point of time, 
old studies may not reflect the current frequency of disease.
The reference population. The reference intervals for 
a specific biological test vary with the population tested. 
Preferably this population should be as similar as possible 
to the population on which the test is going to be used, 
except for the presence of disease [11, 12]. This means 
Int Marit Health 2017; 68, 2: 90–98
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Figure 2 Test sensitivity: the proportion of people with disease 
that have a positive test result
The positive and negative predictive values. How reliable 
is a test result? The positive predictive value (PPv) is the 
proportion of people with a positive test result who have the 
disease, see Figure 4 where the PPv is 62%, which means 
that 8 out of the 13 with a positive test result actually are 
correctly identified. It is dependent on prevalence (see be-
low), or more precisely, the pre-test probability in the specific 
population where the test is carried out. The PPv increases 
when prevalence increases. Therefore the PPv for a certain 
test carried out on a given population cannot be transferred 
to another population if the prevalence is different [12].
Figure 3. Specificity: the proportion of people without disease 
that will have a negative result
ness could be the result, putting healthy seafarers on shore, 
when they actually could have worked at sea. 
Sensitivity and specificity are characteristics of the 
test used, and cannot be used alone to estimate the 
probability of disease in a single individual [10]. Sensi-
tivity only looks at people with disease, specificity only 
at people without the disease. Sensitivity and specificity 
do not provide information that a positive or a negative 
test result is reliable in a single individual. Different pa-
rameters are needed to do this. Other ways of analysing 
test results can do so.
Figure 4. Positive predictive value: the proportion of people with 
a positive test result that have the disease
Figure 5. Negative predictive value: proportion of those with 
a negative test result who do not have the disease
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Given a sensitivity of 80% and a specificity of 94%; the 
PPv will vary from 40% when prevalence is 5% to 96% when 
the prevalence is 60%. The higher the prevalence, the more 
likely it is that a positive test result actually indicates the 
presence of the disease [10]. 
The negative predictive value (NPv) is the proportion of 
those with a negative test result who do not have the disease 
[10, 12], see Figure 5 where 87 individuals are identified 
as not having the disease, whilst this is true only for 85 of 
them. In this case the NPv is 85/87 = 97.7%.
It depends on prevalence, more precisely the pre-test 
probability, and decreases as prevalence increases, exactly 
the opposite to the PPv. 
again you cannot use the NPv for a given test on 
a specific population without checking that the prevalence 
is the same. If it is not, another NPv must be calculated. In 
the example above, the NPv will go down from 99% when 
prevalence is 5% to 76% when prevalence is 60%. The 
higher the prevalence, the less likely it is that a negative 
test result is reliable [10].
In the discussion of whether the test should be includ-
ed in the programme, these values are of importance to 
consider.
The cut-off points. The accuracy of a diagnostic test is 
described by the sensitivity and the specificity of the test. 
Both of them are dependent on the chosen cut-off point 
between normal and abnormal. The higher the cut-off point, 
the higher the sensitivity, but the lower the specificity.
laboratory tests and imaging techniques currently used 
in PeMe protocols have not been developed for the assess-
ment of a risk that might occur at sea when a certain medical 
condition is present. Some conditions are easily treated on 
board; others lead to medical evacuation, diversion, hospi-
talisation, repatriation and replacement. The way we decide 
on the cut-off points is highly dependent on the objectives 
of the PeMe protocols. 
tESt SAFEtY
when testing asymptomatic and therefore presumably 
healthy people with no indication of disease, it is important 
that the test itself does not impose a risk to the individual. 
Invasive techniques could have a potential of causing harm, 
as well as procedural deficiencies. It is in our opinion un-
ethical to expose the individual seeking employment at sea 
to an individual risk of harm to his or her own health in the 
process of screening. we believe that potentially hazardous 
procedures should not be a part of a PeMe examination.
tESt cOStS
The cost of a test could be considerable and its wide-
spread use may not result in a decrease in costs incurred 
due to a reduction of medical incidents occurring at sea. 
How many people must be screened using the test in 
order to ‘save’ the cost of one medical evacuation? In the 
clinical example of ultrasound scan (USS) for gall stones 
(Table 3), it will cost around £1,000,000 to avoid two 
medevacs due to a gall stone attack. The people who are 
paying for the USS are often not those who are paying for 
the evacuation costs, repatriation and replacement. In the 
assessment of the appropriateness of a test, the overall 
cost picture should be considered. If the cost of the many 
tests required is higher than the likely expenses that will be 
incurred if the test is not used, it should not be included in 
the PeMe protocol unless it reveals an unacceptable risk 
whilst serving on board. 
A cLINIcAL EXAMPLE: ULtrASOUND  
ScAN OF tHE GALLbLADDEr IN 
ASYMPtOMAtIc SEAFArErS
In the worked example in Table 3 we are putting 10,000 
seafarers through an USS at a cost of approximately 
£100 per scan i.e. £1,000,000 to prevent two potential 
medevacs for hospital care over the next 2 years amongst 
the subgroup found to have incidental but asymptomatic 
gallstones. 
In the meantime 313 seafarers will go to sea with gall-
stones not picked up on the scan and therefore despite 
this cost and of these 10 (9.4) may develop symptoms and 
1 (0.5) will require hospital treatment and possible evacu-
ation and repatriation.
Table 3. Gallstones in the United Kingdom (UK) — statistical data
Consider a population of 10,000 seafarers in the UK
Prevalence: 15% of UK population has gallstone disease  
according to the National Institute for Health and Care  
excellence (NICe) i.e. 1500 of 10,000 seafarers
The sensitivity of ultrasound scan (USS) for gallstones is 79%  
so of those 1500, USS will correctly identify gallstones in  
1187 seafarers. Therefore 313 seafarers will be missed  
by USS and go to sea with their gallstones.
The risk of symptoms occurring in asymptomatic patient with 
gallstones is 1–2% per year i.e. 2–4% over the 2 year validity 
period of the certificate [16–21] 
Therefore 3% of 1187 seafarers with known gallstones i.e.  
36 seafarers will suffer symptoms related to gallstones over  
the next 2 years. Of these seafarers who develop symptoms,  
5% will need hospital care [15] and therefore potentially  
evacuation and repatriation i.e. 2 seafarers.
at the same time 1151 seafarers will be asymptomatic from the-
re incidental gallstones and have been kept on land for no good 
reason. Some may have undergone surgery that would not be  
clinically indicated with the associated risk of the procedure 
itself plus the risk of complications e.g. adhesions over the 
validity period of their next certificate. Serious complications of 
endoscopic cholecystectomy occur in 2.6% [14]
Int Marit Health 2017; 68, 2: 90–98
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Put another way we must screen 5,000 UK seafarers 
and recommend elective cholecystectomy in 593 sea-
farers to save symptoms occurring whilst at sea in the 
next 2 years in 18 seafarers and a potential medevac 
in one case. 
The prevalence of gallstones is higher in western 
countries than in others [13], so in countries with a lower 
incidence of gallstones, e.g. Philippines, it is likely that 
even more seafarers would need to be screened (and 
potentially stopped from going to sea) in order to prevent 
one medevac. 
tESt AvAILAbILItY
The test should be available wherever the seafarers 
are having their PeMe to ensure fair and equal assess-
ment of the seafarers. The need for referral to a specialist 
make the test less useful and possibly less likely to be 
used, which reduces the relevance of including the test 
in a test programme. 
IMPrOvED rISK ASSESSMENt
This is the salient point in the assessment. The over-
all objective of the PeMe is to reduce the incidence of 
medical incidents at sea imposing a risk to crew, ship 
and self. Incidence data are available only to a limited 
extent, and structured evaluation of reduction of risk 
at sea by the use of screening tests in PeMe, is to our 
knowledge, not yet published. even if the tests cannot 
be properly validated statistically due to a lack of back-
ground data, some conclusions on the appropriateness 
can be reached through the structured process of as-
sessing the tests.
Table 4. Suggested decision aid for the assessment of the appropriateness of biochemical tests and imaging techniques in  
pre-employment medical examinations (PeMe)
Step Description
1 Identification of disease with the likelihood of unacceptable risk to ship, crew and self — and which can be  
identified by a specific test
• Which medical incidents could the disease lead to
• What is the likely incidence (per year) for such incidents given established diagnosis
2 which test is considered to screen asymptomatic individuals?
3 which mitigating measures can a positive test result lead to?
4 Is the test considered capable of detecting the disease at an asymptomatic stage? 
• Consider the appropriate statistical parameters 
5 Is the test safe? 
6 • Is the test cost effective? Are potential savings greater than the likely costs to be incurred without the test?
• Calculate number needed to test to avoid one medical incident over the next 2 years
7 Is the test available to all seafarers internationally without need for further referral?
8 Can use of the test lead to a demonstrable improvement in risk assessment? 
9 CONClUSION: Is the screening test appropriate to manage risk to an acceptable level?
PrOPOSED FLOWcHArt FOr A DEcISION 
AID tO ASSESS tHE APPrOPrIAtENESS 
OF tHE USE OF ScrEENING tEStS IN 
ASYMPtOMAtIc SEAFArErS 
Table 4 presents decision aid for the use of additional 
tests during the PeMe of seafarers.
DIScUSSION 
The lack of consensus discussions between the different 
parties with regards to the level of risk that can be tolerated 
has led to the development of numerous PeMe protocols 
with a different number and combinations of screening tests. 
Therefore, a seafarer can receive a different decision on fit-
ness to work at sea from different protocols. a series of ques-
tions arises in this respect. which diseases are necessary 
to avoid? which diseases can be accepted? which tests are 
useful and which are useless, for risk assessment? To what 
extent can seafarers be allowed to work at sea if disease risk 
factors are present or an asymptomatic diagnosis has been 
made? How can we use limitations in time and restrictions in 
sailing area and position on board in an evidence-based way 
to mitigate risk related to underlying medical conditions? Can 
we agree on the objectives for the PeMe? why do we need 
different protocols? How can we do this in an ethical way? 
The questions and answers must be considered from the 
perspective of maritime authorities, seafarers, shipowners 
and insurers. Using the example above, the seafarer may 
well feel that a risk of less than 1% of symptomatic gall-
stones over the next 2 years is a risk worth taking compared 
the alternative of paying for an USS and potentially having 
to undergo elective surgery with its own risks, whilst he is 
losing money as he is unable to work during this time. On 
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the other hand that risk of symptoms from gall stones and 
the chance of a medevac maybe too high for a shipowner 
or insurer at a time when margins are tight and any pre-
ventable interruption to operations and loss of productivity 
is not acceptable. 
In medical conditions and screening tests with a vari-
able scale rather than a yes or no answer the situation 
becomes even less clear. Ideally if such a test is to be used 
there should be a clear cut off point at which the seafarer 
is fit or unfit for work at sea. This may or may not be the 
same cut off point at which treatment for that condition 
is required. 
The tests used to screen asymptomatic seafarers 
in PeMe should preferably be validated for their use in 
this context. Important data for such validation, such as 
reference population data on prevalence and incidence 
are lacking, and data from the general population will 
have to be used. Currently there is no agreement on the 
appropriate cut off points for the tests being used as far 
as we are aware and there is no agreement on the level 
of risk that can be accepted. This makes it difficult to 
assess the appropriateness of the different tests used in 
PeMe. as part of the process of deciding whether or not to 
adopt a test as part of a PeMe examination there must be 
a discussion, and hopefully agreement, on the level of risk 
and therefore potential cost that can be tolerated by the 
different parties.
cONcLUSIONS
Despite the recommendation from the UN agencies 
that laboratory tests and imaging techniques should not 
be used in the absence of an individual clinical indication, 
they are widely used for screening prior to employment on 
board ship. whilst some may be a useful risk management 
tool in the assessment of seafarers others may offer no 
reduction in risk at sea whilst at the same time incur-
ring significant costs for those paying, risks to seafarers 
of treating asymptomatic conditions or putting healthy 
seafarers ashore. Discussions are needed between the 
parties responsible for specifying and for working within 
different PeMe protocols to seek consensus. Because 
of differences in prevalence, some screening tests may 
be useful in some populations but not others and hence 
recommendations should be tailored to the local need in 
the different areas where seafarers are recruited. There is 
also a need to develop criteria for use when new techniques 
are being considered. The stepwise approach suggested 
in this article provides a starting point for discussion and 
review of the use of such tests. However, a holistic individ-
ual risk assessment that is based on all the available valid 
information collected during the PeMe and performed by 
a health professional with competence in maritime medi-
cine should form the basis for decisions on the certification 
of fitness in all PeMe protocols. 
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